Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $20

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $20.